Skip to main content
main-content

2021 ASCO Annual Meeting coverage

News and expert insight from the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
News highlight | Genitourinary cancers

KEYNOTE-564 supports adjuvant pembrolizumab use in high-risk RCC patients

News highlight | Breast cancer

‘Excellent’ outcomes with de-escalated neoadjuvant early breast cancer regimen

Video highlight | Lung and thoracic cancers

Patritumab deruxtecan shows promise for EGFR inhibitor-resistant NSCLC

More on breast cancer

Matteo Lambertini

18-06-2021 | ASCO 2021 | Conference coverage | Video

Clinical insights into breast cancer trials

Matteo Lambertini comments on the early and advanced breast cancer trials that caught his attention at the 2021 ASCO Annual Meeting, including the OlympiA, ECOG-ACRIN EA1131, GeparNUEVO, DAWNA-1, and sysucc-002 studies.

Jennifer Litton

18-06-2021 | ASCO 2021 | Conference coverage | Video

Neoadjuvant talazoparib active in BRCA-mutated early breast cancer

Jennifer Litton discusses results of the NEOTALA trial suggesting patients with germline BRCA1/2-mutant, HER2-negative, early breast cancer may benefit from neoadjuvant treatment with talazoparib.

Ingrid Mayer

14-06-2021 | ASCO 2021 | Conference coverage | Video

Capecitabine remains the postoperative standard of care for TNBC with residual disease

Ingrid Mayer discusses findings from the ECOG-ACRIN EA1131 trial showing no benefit of postoperative platinum-based chemotherapy versus capecitabine in patients with triple-negative breast cancer who have residual disease following neoadjuvant chemotherapy.

More on genitourinary cancers

Petros Grivas

18-06-2021 | ASCO 2021 | Conference coverage | Video

Additional insights from JAVELIN Bladder 100

Petros Grivas outlines the latest analyses of the JAVELIN Bladder 100 study of maintenance avelumab in metastatic urothelial cancer, including the assessment of efficacy by clinical and molecular subgroups and by the post-chemotherapy treatment-free interval, as well as data on time to end of subsequent therapy.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Arjun Balar

17-06-2021 | ASCO 2021 | Conference coverage | Video

INDUCE-1 points to ICOS agonist activity in advanced urothelial cancer

Arjun Balar talks through the INDUCE-1 trial findings for patients with advanced urothelial carcinoma who were given the ICOS agonist feladilimab alone or alongside pembrolizuamb.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Peter O’Donnell

14-06-2021 | ASCO 2021 | Conference coverage | Video

Pembrolizumab benefit confirmed for cisplatin-ineligible advanced UC patients

Peter O’Donnell gives an update on the KEYNOTE-052 trial findings for first-line pembrolizumab in cisplatin-ineligible patients with advanced urothelial carcinoma.

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

More on thoracic cancers

Gilberto Lopes

22-06-2021 | ASCO 2021 | Conference coverage | Video

Lung cancer: Clinical insights into key research

Gilberto Lopes shares his lung cancer highlights from the 2021 ASCO Annual Meeting, including the IMpower010 trial, the MYLUNG study of real-world molecular testing, and updates on the CodeBreaK 100 and CHRYSALIS studies.

Heather Wakelee

15-06-2021 | ASCO 2021 | Conference coverage | Video

IMpower010 supports adjuvant atezolizumab in early-stage NSCLC

Heather Wakelee talks through the efficacy and safety data from the IMpower010 study of postoperative atezolizumab in individuals with early-stage non-small-cell lung cancer, touching on the cost aspect and outlining the key unanswered questions.

Stephen Liu

05-06-2021 | ASCO 2021 | Conference coverage | Video

ARROW update confirms pralsetinib benefit for RET fusion-positive advanced NSCLC

Stephen Liu talks through the latest findings from the ARROW trial of pralsetinib for patients with RET fusion-positive advanced non-small-cell lung cancer.


Medicine Matters conference coverage is brought to you in partnership with medwireNews